Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
56 hedge funds and large institutions have $12.5M invested in Zynerba Pharmaceuticals, Inc in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.
173% more call options, than puts
Call options by funds: $109K | Put options by funds: $40K
5% less funds holding
Funds holding: 59 → 56 (-3)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
50% less capital invested
Capital invested by funds: $24.9M → $12.5M (-$12.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$520K |
| 2 |
Millennium Management
New York
|
+$387K |
| 3 |
Two Sigma Advisers
New York
|
+$69.4K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$47.9K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$39.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.55M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$271K |
| 3 |
Two Sigma Investments
New York
|
-$221K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$193K |
| 5 |
Jane Street
New York
|
-$130K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Simplex Trading
Chicago,
Illinois
| – | -$1.25K | -981 | Closed |
|
|
PFS
52
Prospera Financial Services
Dallas,
Texas
| – | -$1K | -400 | Closed |
|
|
FFA
53
Freedman Financial Associates
Peabody,
Massachusetts
| – | -$1K | -300 | Closed |
|
|
HI
54
Harbour Investments
Madison,
Wisconsin
| – | +$127 | +100 | New |
|
55
Citigroup
New York
| – | +$176 | +138 | New |
|
56
Bank of America
Charlotte,
North Carolina
| – | +$382 | +300 | +297% |
|
ZYNE Hedge Fund Activity: Q2 2022 in Review
56 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q2 2022, worth a combined $12.5M — down 50% from $24.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ZYNE and 9 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Renaissance Technologies, adding an estimated $520K. The largest seller was ETF Managers Group, cutting an estimated $1.55M.
- 56 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q2 2022, down from 59 in Q1 2022.
- Funds reported $12.5M of Zynerba Pharmaceuticals, Inc stock for Q2 2022, down 50% quarter-over-quarter.
- 9 funds opened new Zynerba Pharmaceuticals, Inc positions in Q2 2022 and 12 closed out, a net change of -3 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q2 2022 was Renaissance Technologies, an estimated $520K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q2 2022 was ETF Managers Group, an estimated $1.55M sold.
Based on aggregated 13F filings for Q2 2022.